Koers ImmunoPrecise Antibodies Ltd. Toronto S.E.
Aandelen
IPA
CA45257F2008
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 17,96 mln. 16,77 mln. | Omzet 2025 * | 29,82 mln. 21,78 mln. 20,34 mln. | Marktkapitalisatie | 44,05 mln. 32,18 mln. 30,04 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,77 mln. -8,18 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,57 mln. -6,14 mln. | EV/omzet 2024 * | 1,79 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,48 x |
K/w-verhouding 2024 * |
-3,48
x | K/w-verhouding 2025 * |
-4,71
x | Werknemers | 102 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over ImmunoPrecise Antibodies Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,86% | 87,31 mld. | |
+3,95% | 40,86 mld. | |
-21,94% | 29,36 mld. | |
+53,11% | 24,49 mld. | |
-5,41% | 17,31 mld. | |
-44,23% | 11,26 mld. | |
-17,60% | 11,62 mld. | |
-13,96% | 11,31 mld. | |
-0,22% | 8,31 mld. |